
|Articles|March 1, 2002
Oritavancin shortens treatment time for complicated skin-structure infections
Chicago - Oritavancin (InterMune), an investigational glycopeptidewith activity against a wide range of Gram-positive pathogens, has beenshown to cut the treatment time in half for complicated skin and skin structureinfections (CSSIs) compared to current standard therapy with vancomycinplus cephalexin, Margaret Wasilewski, M.D., said at the 41st InterscienceConference on Antimicrobial Agents & Chemotherapy.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
The Weekly Roundup: January 12-16
3
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5


















